Press

Field Trip Health & Wellness Obtains CCAA Protection

Mar 23 • 3 min read

Field Trip Health & Wellness Ltd. (TSX-V: FTHW) today announced that it has obtained an Order (the “Initial Order”) for creditor protection from the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”). PricewaterhouseCoopers Inc. has been appointed as the CCAA monitor (the “Monitor”). After careful consideration of the…

Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article

Mar 23 • 2 min read

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that, in its March 17, 2023 issue, Medical Xpress, has published an article titled “Study hints at the promise of non-hallucinogenic LSD for treating mood disorders,” which is based on BetterLife’s…

Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham

Mar 23 • 3 min read

Diamond Therapeutics Inc., a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, is pleased to announce the FDA’s authorization of the IND application submitted by collaborator Dr. Peter Hendricks. The FDA’s authorization allows Dr. Hendricks to proceed with a human clinical trial evaluating the effects of repeat low…

Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023

Mar 23 • 1 min read

Numinus Wellness Inc. (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Sequire Cannabis & Psychedelics Conference to be held virtually on Wednesday, April 5, 2023. Payton Nyquvest, Founder and CEO of Numinus, will present at 10:00 a.m. ET / 7:00 a.m. PT. To…

Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023

Mar 21 • 3 min read

Numinus Wellness Inc. (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Reid Robison, Chief Clinical Officer of Numinus, has contributed to studies published in four peer-reviewed papers thus far in 2023 for his work in the treatment of mental health disorders including Post-Traumatic Stress…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441